Newborn screening for XXXX : effect on mortality.

@entity1 @entity295 @entity66 @entity3458 @entity814 @entity693 @entity8453 @entity6750 @entity204 @entity1624 @entity2395
Newborn screening for @entity3458 has been recommended as a method of decreasing @entity1 mortality. However, its effectiveness in accomplishing this has not been reliably measured. To help determine the effectiveness, 10 years of experience in newborn screening have been summarized. The effects of early @entity1 enrollment in a comprehensive treatment program on long-term morbidity and mortality are reported. From 1975 to 1985, 84,663 newborns were screened regardless of race or ethnic background. Bart's hemoglobin was present in 5%, hemoglobin AS in 2.6%, and hemoglobin AC in 0.75%. Excluding Bart's, approximately 3.6% of all newborns were carriers for @entity8453 . @entity3458 occurred in 1:951 births (58 hemoglobin SS, 25 hemoglobin FSC, three hemoglobin S-beta +- @entity2395 , and three hemoglobin S-beta @entity2395 ). In addition, one in every 4,233 newborns had a clinically significant @entity2395 (eight hemoglobin FE, ten hemoglobin F only, two hemoglobin H). Compared with other newborn screening programs in California, ( @entity6750 , 1:3,849; @entity814 1:22,474, @entity1624 1:74,103), @entity8453 are the most prevalent @entity66 . Eighty-one newborns with @entity3458 were followed for 7.2 years. @entity1 experienced 513 hospitalizations, including 13 episodes of @entity295 with or without @entity693 and ten acute sequestration crises. The overall mortality rate for @entity1 with @entity3458 diagnosed in the newborn period was 1.8%. In comparison, the clinical course of 64 @entity1 with @entity3458 diagnosed after 3 months of age and followed for an average of 9.4 years was analyzed. Five of these @entity1 died. In two of these, @entity3458 was diagnosed at the time of the @entity204 .(ABSTRACT TRUNCATED AT 250 WORDS)
